Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT05640843 Recruiting - Multiple Myeloma Clinical Trials

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Start date: November 29, 2022
Phase: N/A
Study type: Interventional

The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.

NCT ID: NCT05597345 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Start date: August 21, 2023
Phase: Phase 2
Study type: Interventional

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

NCT ID: NCT05469893 Recruiting - Multiple Myeloma Clinical Trials

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Start date: August 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: - Teclistamab - Lenalidomide (also called Revlimid) - Dexamethasone (also called Decadron)

NCT ID: NCT05361694 Recruiting - Multiple Myeloma Clinical Trials

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

TRANSFORMM
Start date: April 12, 2022
Phase:
Study type: Observational

The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

NCT ID: NCT05312255 Recruiting - Plasma Cell Myeloma Clinical Trials

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

NCT ID: NCT05283993 Recruiting - Multiple Myeloma Clinical Trials

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Start date: July 1, 2021
Phase:
Study type: Observational

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

NCT ID: NCT05136807 Recruiting - Clinical trials for Monoclonal Gammopathy of Undetermined Significance

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Start date: June 7, 2016
Phase:
Study type: Observational

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.

NCT ID: NCT05055063 Recruiting - Myeloma Clinical Trials

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Start date: May 18, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and a dose-expansion part. The maximum number of enrolled patients will be 30 with 18 patients for the dose-finding part and 12 patients for the dose-expansion part. Once we determine the MTD or RP2D in the dose-finding part, we will enroll and treat 12 additional patients at the MTD or RP2D in the expansion part. Efficacy will be assessed through the overall response rate (ORR) at the end of the study. With the limited number of patients for the dose-expansion part, we will not have formal futility monitoring rule.

NCT ID: NCT05047107 Recruiting - Multiple Myeloma Clinical Trials

Biology and Genetics of Smouldering Myeloma

COSMOS
Start date: April 15, 2021
Phase:
Study type: Observational

Observational clinical trial recruiting Smouldering Myeloma patients (SMM) or potential SMM patients. Study involves collecting blood and bone marrow samples to determine the features of the tumour genome and BM microenvironment, including immune dysfunction that are key drivers of progression from precursor conditions (MGUS and SMM) to MM.

NCT ID: NCT05014646 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.